Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPX-351 (daunorubicin + cytarabine) (Jazz Pharmaceuticals plc, 041b4c)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CPX-351 (Vyxeos) is a liposomal formulation co-encapsulating the anthracycline daunorubicin and the pyrimidine analogue cytarabine in a fixed 1:5 molar ratio. This specific ratio has been shown in preclinical models to maximize synergistic antileukemic activity. The liposomal delivery system (CombiPlex platform) enhances the pharmacokinetics of the drugs, allowing for prolonged exposure and preferential uptake by leukemic cells in the bone marrow. Daunorubicin acts by intercalating into DNA and inhibiting topoisomerase II, while cytarabine acts as an antimetabolite that inhibits DNA polymerase and incorporates into DNA, leading to chain termination. CPX-351 is FDA-approved for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
- Brand names
- Vyxeos
- Other names
- Liposomal daunorubicin-cytarabinedaunorubicin and cytarabine liposome
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on CPX-351 (daunorubicin + cytarabine) (Jazz Pharmaceuticals plc, 041b4c).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPX-351 (daunorubicin + cytarabine) (Jazz Pharmaceuticals plc, 041b4c).